GlassScriptPhysician profile
Matthew L Cobb
NPI 1497866099
$2,086.67
in general payments reported to CMS, 2019-2025
26 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $27.01 · 2021: $254 · 2022: $184 · 2023: $168 · 2024: $578 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $276.42 | 2021-2025 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $238.69 | 2020-2025 | Breztri, Airsupra |
| Amgen INC. | $222.03 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $203.47 | 2019-2024 | |
| Novo Nordisk INC | $191.50 | 2024-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $158.35 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $141.87 | 2021-2024 | Ubrelvy |
| Glaxosmithkline, LLC. | $113.87 | 2021-2025 | Shingrix, Bexsero, Arexvy |
| Astellas Pharma US INC | $88.68 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $61.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.38 | 2024-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $36.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $34.04 | 2024 | Quviviq |
| Globus Medical, INC. | $32.42 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $30.37 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $28.54 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $24.00 | 2019 | |
| Esperion Therapeutics, INC. | $21.64 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.65 | 2025 | Monoferric |
| Otsuka America Pharmaceutical, INC. | $20.29 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $18.54 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.22 | 2025 | Jardiance |
| Boston Scientific Corporation | $15.16 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.29 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.96 | 2021 | |
| Ge Healthcare | $10.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.